References

1. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ et al.. (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature, 468 (7320): 93-7. [PMID:20962779]

2. Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ, Pepys MB. (1997) Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med, 3 (8): 855-9. [PMID:9256275]

3. Richards DB, Cookson LM, Barton SV, Liefaard L, Lane T, Hutt DF, Ritter JM, Fontana M, Moon JC, Gillmore JD et al.. (2018) Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Sci Transl Med, 10 (422). [PMID:29298867]

4. Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, Fontana M, Moon JC, Pinzani M, Gillmore JD et al.. (2015) Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med, 373 (12): 1106-14. [PMID:26176329]

5. Tennent GA, Lovat LB, Pepys MB. (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA, 92 (10): 4299-303. [PMID:7753801]